https://sputnikglobe.com/20210318/six-month-old-baby-in-chile-receives-sinovacs-covid-19-vaccine-by-accident-reports-suggest-1082385224.html
Six-Month-Old Baby in Chile Receives Sinovac's COVID-19 Vaccine by Accident, Reports Suggest
Six-Month-Old Baby in Chile Receives Sinovac's COVID-19 Vaccine by Accident, Reports Suggest
Sputnik International
MOSCOW (Sputnik) - A six-month-old baby in Chile has been accidentally inoculated with the COVID-19 vaccine by China's Sinovac, the 24 Horas broadcaster... 18.03.2021, Sputnik International
2021-03-18T17:38+0000
2021-03-18T17:38+0000
2021-03-18T17:38+0000
https://cdn1.img.sputnikglobe.com/img/105766/62/1057666210_0:191:1920:1277_1920x0_80_0_0_eb207ecbd6f0c615ef6f92d5d4427dd8.jpg
chile
china
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2021
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
https://cdn1.img.sputnikglobe.com/img/105766/62/1057666210_0:71:1920:1277_1920x0_80_0_0_597db6fd7858ba40fffe3440270585e0.jpgSputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
newsfeed, latin america, chile, china
newsfeed, latin america, chile, china
Six-Month-Old Baby in Chile Receives Sinovac's COVID-19 Vaccine by Accident, Reports Suggest
MOSCOW (Sputnik) - A six-month-old baby in Chile has been accidentally inoculated with the COVID-19 vaccine by China's Sinovac, the 24 Horas broadcaster reported Thursday, citing local authorities.
According to the news outlet, the child was vaccinated after the mother brought them to a family health center in the commune of Tirua in the Bio Bio region for age-appropriate vaccine shots.
The commune said that it had relayed information to all corresponding authorities and took all necessary measures to observe the baby. So far, the baby has not shown any negative reactions.
The investigation into the incident is underway.
Sinovac started developing its vaccine back in January 2020. The vaccine has been approved for Phase III clinical trials in Brazil, Indonesia, Turkey and Chile, while the Phase I and II trials' results in China have shown that the vaccine is capable of inducing antibodies in over 90 percent of volunteers who received two doses.